BioMarin Pharmaceutical Quarterly Balance Sheet
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioMarin Pharmaceutical financial position
As of Jun 30, 2026, BioMarin Pharmaceutical reported total assets of $11.72 billion, up 57.2% from a year earlier against total liabilities of $5.40 billion. Shareholders' equity stood at $6.32 billion, or 53.9% of assets. The company held $874.0 million in cash and equivalents against $4.19 billion of debt, a net debt position of $3.31 billion.
The current ratio (current assets divided by current liabilities) was 2.39, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.66.
Summary generated from market data by MetaCap's automated system. Methodology
BioMarin Pharmaceutical balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 874.00M | 2.22B | 1.31B | 1.25B | 1.21B | 1.05B | 942.84M | 675.45M | 972.15M | 747.00M | 755.13M | 785.41M |
| Short-Term Investments | 0 | 0 | 248.93M | 227.73M | 218.31M | 223.53M | 194.86M | 255.00M | 252.20M | 299.58M | 318.68M | 340.43M |
| Receivables | 1.06B | 903.91M | 908.21M | 790.27M | 855.86M | 739.18M | 660.53M | 777.55M | 691.23M | 637.16M | 633.70M | 572.50M |
| Inventory | 1.78B | 1.27B | 1.30B | 1.38B | 1.34B | 1.27B | 1.23B | 1.18B | 1.18B | 1.14B | 1.11B | 1.03B |
| Total Current Assets | 3.97B | 4.61B | 3.95B | 3.85B | 3.81B | 3.47B | 3.23B | 3.06B | 3.26B | 2.99B | 2.96B | 2.96B |
| Property, Plant & Equipment | 989.99M | 958.07M | 952.51M | 1.04B | 1.03B | 1.03B | 1.04B | 1.05B | 1.05B | 1.06B | 1.07B | 1.07B |
| Goodwill | 655.75M | 196.20M | 196.20M | 196.20M | 196.20M | 196.20M | 196.20M | 196.20M | 196.20M | 196.20M | 196.20M | 196.20M |
| Intangible Assets | 4.88B | 204.66M | 213.84M | 233.11M | 239.62M | 247.35M | 255.28M | 260.92M | 265.53M | 279.65M | 294.70M | 302.48M |
| Long-Term Investments | 0 | 0 | 492.24M | 512.94M | 508.59M | 506.72M | 521.24M | 561.99M | 557.08M | 620.55M | 611.13M | 548.00M |
| Total Assets | 11.72B | 8.59B | 7.59B | 7.61B | 7.46B | 7.15B | 6.99B | 6.85B | 7.07B | 6.87B | 6.84B | 6.76B |
| Accounts Payable | 1.01B | 793.15M | 759.03M | 798.44M | 684.25M | 628.21M | 606.99M | 715.66M | 572.50M | 593.54M | 683.15M | 669.83M |
| Short-Term Debt | 658.20M | — | 0 | — | — | — | — | — | — | — | — | — |
| Total Current Liabilities | 1.66B | 793.15M | 759.03M | 798.44M | 684.25M | 628.21M | 606.99M | 715.66M | 1.07B | 1.09B | 1.18B | 1.16B |
| Long-Term Debt | 3.53B | 1.43B | 597.18M | — | — | — | — | — | — | — | — | — |
| Total Liabilities | 5.40B | 2.38B | 1.51B | 1.56B | 1.43B | 1.35B | 1.33B | 1.44B | 1.78B | 1.80B | 1.89B | 1.86B |
| Shareholders' Equity | 6.32B | 6.21B | 6.09B | 6.06B | 6.03B | 5.79B | 5.66B | 5.41B | 5.29B | 5.07B | 4.95B | 4.90B |
| Retained Earnings | 304.50M | 259.73M | 154.21M | 200.78M | 231.52M | -9.01M | -194.69M | -319.64M | -425.72M | -532.89M | -621.55M | -641.93M |
| Total Debt | 4.19B | 1.43B | 597.18M | — | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | -3.31B | 792.15M | 963.43M | 1.48B | 1.43B | 1.27B | 1.14B | 930.44M | 1.22B | 1.05B | 1.07B | 1.13B |
| Shares Outstanding | 193.54M | 193.27M | 192.30M | 192.10M | 192.00M | 191.76M | 190.76M | 190.55M | 190.36M | 189.78M | 188.60M | 188.34M |
This table shows 12 quarterly periods of BioMarin Pharmaceutical's balance sheet, from Q2 2026 back to Q3 2023, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BMRN's reporting calendar. What is a balance sheet?